Pabau GO app

The new Pabau GO is heredownload on the App Store

Download on the App Store
Book a demo Book a demo
Aesthetic Clinic

Aesthetics non-CQC: Sculptra consent

Key Takeaways

Key Takeaways

Sculptra is a poly-L-lactic acid (PLLA) biostimulator that stimulates collagen production over multiple sessions, not a traditional dermal filler.

Non-CQC registered UK aesthetic clinics can legally provide non-surgical Sculptra treatments but must follow Montgomery v Lanarkshire informed consent standards and disclose all material risks.

The form must cover the palpable nodule risk, multi-session treatment protocol (typically 3-4 sessions at 3-week intervals), and delayed onset of results (2-4 weeks after final session).

Pabau’s digital consent forms streamline GDPR-compliant record-keeping and reduce paperwork by automating e-signature workflows for aesthetic clinics.

A comprehensive informed consent form for non-CQC registered UK aesthetic clinics. Covers patient details, PLLA mechanism, contraindications, multi-session protocols, risk disclosures, and practitioner qualification declarations for Sculptra treatments.

Download template

This guide explains what your Sculptra consent form must include, how to ground it in UK law, and why dermal filler consent forms alone won’t suffice for a PLLA biostimulator. We’ll walk you through building a consent framework that protects both your patients and your clinic.

A Sculptra consent form is a legal document that documents a patient’s informed agreement to undergo poly-L-lactic acid (PLLA) injection treatment. Unlike hyaluronic acid fillers (Juvederm, Restylane) that work immediately, Sculptra stimulates the patient’s own collagen production, requiring a multi-session treatment plan with delayed results.

The form serves three critical functions: it ensures the patient understands the treatment mechanism and timeline, it discloses material risks (including the risk of palpable but non-visible nodules), and it confirms the patient has had the opportunity to ask questions before treatment.

Under the Montgomery v Lanarkshire Health Board [2015] case law, UK practitioners must disclose all risks a reasonable patient would want to know about – not just risks a practitioner believes are material.

For non-CQC registered aesthetic clinics, this form also serves as documentary evidence of professional care. Regulatory bodies including the JCCP (Joint Council for Cosmetic Practitioners) and Save Face accreditation scheme expect clinics to maintain detailed, signed consent records. Digital consent documents — stored securely in compliance with UK GDPR — strengthen both patient safety and clinic liability protection.

The template follows a five-step clinical workflow that mirrors how aesthetic practitioners actually deliver Sculptra treatment:

  1. Patient Details Section: Capture name, date of birth, contact information, and medical history screening questions (current medications, allergies, pregnancy status, previous adverse reactions to injectables). This section establishes the baseline for risk stratification.
  2. PLLA Mechanism Explanation: Describe what Sculptra does in patient-friendly language. The form explains that Sculptra works differently from traditional fillers – it stimulates collagen production gradually, with results appearing 2-4 weeks after the final injection session.
  3. Multi-Session Treatment Plan Acknowledgement: Explicitly state that Sculptra treatment typically requires 3-4 sessions spaced 3 weeks apart. The patient must acknowledge they understand the full commitment before the first injection.
  4. Risk and Contraindication Checklist: List absolute contraindications (active infection at injection site, known PLLA allergy, severe bleeding disorders) and relative contraindications (pregnancy, breastfeeding, active inflammatory skin conditions). Include the specific risk of palpable nodules – these may be felt by the patient but are typically asymptomatic and non-visible.
  5. Informed Consent Declaration and Signature Block: Final paragraph where the patient confirms they have read the form, understand the treatment and risks, and authorize the practitioner to proceed. Include signature lines for both patient and practitioner, plus date of treatment.

Store the completed form in a digital consent management system that uses e-signatures. This reduces paperwork and ensures digital consent records are stored securely in compliance with UK GDPR. Every signature should be timestamped and the record linked to the patient’s clinical file for audit trails.

Customizable consent and intake forms
Customizable consent and intake forms

This template is designed for non-CQC registered aesthetic clinics in England offering Sculptra treatments. This includes independent aesthetic practitioners, medical spas, beauty clinics with injectable services, and small aesthetic teams. It is equally relevant to practitioners in Scotland, Wales, and Northern Ireland – though regulations differ by region, the informed consent standard under Montgomery case law applies UK-wide.

The form is particularly valuable for practitioners who want to offer medical spa clinic management software that handles both clinical workflows and consent tracking. If your clinic has already documented protocols for Botox, dermal fillers, or other injectable procedures, this Sculptra template extends that framework to cover the specific risks and multi-session nature of PLLA treatment.

Practitioners working toward aesthetic practitioner qualification requirements – whether through JCCP membership or Save Face accreditation – will find this form aligns with professional standards for documentation and informed consent.

Compliance with UK informed consent law: The Montgomery ruling requires practitioners to disclose all risks a reasonable patient would want to know. This template ensures no material risk – including the palpable nodule phenomenon – is overlooked.

Protection against liability claims: A signed, dated, detailed consent form creates documentary evidence that you obtained informed agreement before treatment. In the event of a patient complaint or regulatory inquiry, this record demonstrates professional care.

Regulatory readiness: If your clinic pursues CQC registration in the future, or if you want to meet JCCP or Save Face accreditation standards, comprehensive consent documentation is non-negotiable. This template builds that habit from day one.

Patient education and trust: When patients read a detailed, honest consent form that covers both benefits and risks, they gain confidence in your professionalism. Patients who understand the multi-session timeline and delayed results are less likely to express dissatisfaction when results take weeks to appear.

GDPR-compliant digital storage: Use Pabau’s digital consent forms to store signed documents with automatic encryption, audit trails, and secure patient portal access. This meets UK GDPR requirements for patient data protection and reduces physical paperwork storage costs.

Pro Tip

Track when each patient signed their Sculptra consent form and link it to their injection appointment date in your clinical records. If a patient returns months later with questions about their treatment timeline, this linked record proves exactly when they consented and when injections occurred – critical for audit trails and quality assurance.

Non-CQC aesthetic clinic compliance requirements

One common misconception: because Sculptra treatments are non-surgical and non-CQC-regulated, clinics don’t need rigorous consent documentation. This is backwards. Non-CQC clinics have MORE responsibility to demonstrate informed consent, because they lack external regulatory oversight.

In England, the Care Quality Commission regulates surgical cosmetic procedures (surgery requiring general anesthetic) but does NOT regulate non-surgical injectables including Sculptra. This means your clinic won’t have a CQC inspector visiting your premises. But it also means you are the sole steward of patient safety – and consent documentation is your primary evidence of that stewardship.

Instead, follow these standards: JCCP (Joint Council for Cosmetic Practitioners) publishes practitioner conduct guidelines emphasizing informed consent. Save Face accreditation scheme requires members to maintain detailed consent records. The GMC’s Decision making and consent guidance sets the legal framework for any practitioner operating in the UK.

This template reflects all those standards in one document: it covers contraindications screening, multi-session protocols, explicit risk disclosures (palpable nodules, delayed onset, post-treatment massage requirements), and clear consent language. Use it as your baseline – then have your template reviewed by a healthcare law specialist to confirm it reflects any clinic-specific protocols or UK regional regulations that apply to your location.

Sculptra’s most distinctive risk is the palpable nodule phenomenon: small, firm bumps under the skin that patients can feel but usually cannot see. These are usually benign papules caused by the uneven distribution or accumulation of PLLA particles rather than a true inflammatory reaction, and they typically resolve within months without intervention. (True granulomas – a rarer, delayed inflammatory reaction – are a separate complication that may persist and require medical treatment.) But if a patient feels a bump and doesn’t understand what it is, they may panic.

Your consent form must explicitly name this risk in plain language. Example phrasing: “Small, firm bumps (nodules) may develop at the injection site. These are usually not visible but may be felt when touching the treated area. They typically resolve within 2-4 months. If a nodule persists or causes discomfort, notify your practitioner immediately.”

Other key risks to cover: post-treatment swelling and redness (typically resolve within 24-48 hours), asymmetry if one side requires more treatment, infection (rare but requires immediate medical attention), and the small risk of vascular occlusion if injected into a blood vessel. Managing aesthetic treatment risks requires this level of specificity – generic risk disclaimers won’t satisfy informed consent law.

Post-treatment care and consent document follow-up

Your consent form should include a post-treatment care section. Sculptra requires specific post-injection massage: patients must massage the treated area for about 5 minutes, 5 times a day, for 5 days after each session (the commonly cited “rule of 5s”). This massage helps distribute the PLLA particles evenly and reduces nodule formation risk.

Provide written post-care instructions with your consent form – not separately. When instructions are embedded in the same document the patient signed, they’re part of the informed consent agreement.

Include:

  • Massage technique (gentle circular motions with finger or special massage tool),
  • Frequency (5 times a day for 5 days after each session),
  • What to avoid (strenuous exercise, hot showers, facial treatments for 48 hours post-injection),
  • When to contact the clinic (persistent redness after 48 hours, signs of infection, allergic reaction).

Store these post-care instructions linked to the original consent form in your patient record system. When the patient returns for their second or third session, you can review their adherence to the massage protocol – this demonstrates continuity of care and supports your evidence of informed, engaged patient management.

Managing consent documentation manually consumes clinic time and creates compliance slips. Digital consent workflows within practice management software streamline this process. Patients complete forms on a tablet before treatment, e-signatures are captured automatically, and records are encrypted and audit-logged for regulatory compliance. Book a demo to see Pabau in action.

Conclusion

A Sculptra consent form template tailored to UK regulatory standards protects both your patients and your clinic. By documenting informed agreement to PLLA treatment you demonstrate professional care and compliance with Montgomery v Lanarkshire informed consent law.

This template provides the foundation; adapt it to your clinic’s specific protocols and have it reviewed by a healthcare law specialist before implementation. Download the template above and integrate it into your clinic’s digital consent workflow today.

Continue your research

Continue your research

Need guidance on digital patient consent workflows? Patient portal security for consent record access shows how to balance patient privacy with secure document storage.

Want to automate clinical documentation after consent? AI medical scribe for automated clinical notes captures treatment details and links them to the original consent form for complete audit trails.

Looking for a broader compliance checklist? Compliance requirements for aesthetic clinics covers consent, GDPR, insurance, and regulatory pathways for non-CQC aesthetics practices.

Frequently asked questions

What is the legal standard for informed consent in UK aesthetics?

The Montgomery v Lanarkshire Health Board [2015] ruling requires practitioners to disclose all risks a reasonable patient would want to know about before treatment, not just risks the practitioner believes are material. This applies to all UK clinics, whether CQC-registered or not. Your Sculptra form must cover both common risks (swelling, redness) and less common but serious risks (vascular occlusion, infection, persistent nodules).

Can a non-CQC aesthetic clinic legally provide Sculptra in the UK?

Yes. Non-surgical injectable treatments including Sculptra fall outside CQC regulation in England. However, practitioners must hold appropriate qualifications (nursing qualification, medical qualification, or recognized aesthetic training), follow informed consent standards, and comply with GDPR for patient data. Scottish, Welsh, and Northern Irish regulations differ slightly – check your regional requirements before launching treatment.

What risks must the Sculptra consent form explicitly mention?

Essential risks include palpable nodules (firm bumps that patients feel but don’t see), delayed onset (results take 2-4 weeks after final session), post-treatment swelling and redness, asymmetry, infection, and vascular occlusion. Also mention that Sculptra is a biostimulator, not an instant filler – it stimulates the patient’s own collagen production, so timeline expectations differ from hyaluronic acid fillers.

How long should patients wait between Sculptra sessions?

Standard protocol is 3 weeks between sessions. The FDA approval documented up to 4 treatment sessions at three-week intervals for nasolabial fold correction. Your consent form should specify your clinic’s exact session schedule – if you offer 3 sessions or 4 sessions, state this upfront so patients understand the full treatment commitment before signing.

Can I store digital Sculptra consent forms under UK GDPR?

Yes, provided your storage system uses encryption, audit logging, and secure access controls. UK GDPR compliance for patient consent records requires that patient data (including signed consent documents) be encrypted at rest and in transit, with clear data retention policies and patient right-to-access procedures. Practice management software with integrated digital consent forms simplifies this compliance.

×